

Supplemental TableS2: Association between interval from initiation of nivolumab or irinotecan to the first CT evaluation and drugs

Interval from initiation of NIVO or IRI to the first CT evaluation		≤ 6 weeks		> 6 weeks and ≤12 weeks		> 12 weeks		p-value
Rapid group	NIVO (n = 16)	6	(37)	10	(63)	0	0	0.099
	IRI (n = 46)	7	(15)	34	(74)	5	(11)	
Slow group	NIVO (n = 10)	1	(10)	9	(90)	0	0	0.81
	IRI (n = 29)	6	(21)	21	(72)	2	(7)	